Sterilization News and Research

RSS

Women's perceptions of sexual function after gynecologic surgery

Most women scheduled for gynecologic surgery to address noncancerous symptoms said in a recently published survey that they were not worried about the effects of the procedure on their sex lives.

13 Apr 2010

AP examines anticipated changes to U.S. National Security Strategy, use of health diplomacy

The Associated Press looks at some anticipated changes to the "National Security Strategy, a document that previously outlined the Bush Doctrine of preventive war." The article focuses on the prospective strategy changes, but notes that the "revisions are part of a larger effort about which the White House talks openly, one that seeks to change not just how the U.S. talks to Muslim nations, but also what it talks to them about, from health care and science to business startups and education."

8 Apr 2010

Health Robotics introduces Virtual High-Availability Architecture for CytoCare and i.v.STATION robots

As part of its I.V. Room of the Future initiative to cooperate with other industry leaders, Health Robotics today announced the immediate availability of its revolutionary Virtual High-Availability Architecture (up to 99.99%), including state-of-the-art, virtualization compliant, cluster and fail-over, disaster recovery, and back-up solutions for its CytoCare and i.v.STATION robots [with future expansion to TPNstation when available], and its i.v.SOFT Workflow Engine for manual compounding.

7 Apr 2010

FDA grants 510(k) clearance for STERIS SYSTEM 1E Liquid Chemical Sterilant Processing System

STERIS Corporation today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the STERIS SYSTEM 1E® Liquid Chemical Sterilant Processing System.

7 Apr 2010

SE5-OH with Natural S-equol supplement appears to be safe for pre- and post-menopausal women

Healthy pre-and post-menopausal Japanese women who took a supplement of SE5-OH containing Natural S-equol, a novel soy germ-based ingredient under development for the management of menopausal symptoms, had measures of reproductive hormones that stayed within normal limits throughout the study.

3 Apr 2010

Nephros' 2009 product revenues up 81%

Nephros, Inc. announced today financial results for the twelve month period ended December 31, 2009.

3 Apr 2010

Altuglas International launches new acrylic resins for medical devices applications

Altuglas International, a world leader in acrylic plastics, has expanded its family of Medical grade acrylic resins, with Altuglas® CR30 and Altuglas® CR50 impactmodified grades. These resins, feature exceptional alcohols and lipids resistance that reduces environmental stress cracking due to attack of aggressive drugs and disinfectants. These novel acrylic resins are designed for easy injection molding of complex multi-cavity parts.

25 Mar 2010

Nephros and STERIS to develop filtration-based products for medical device applications

Nephros, Inc., a medical device company developing and marketing filtration products for therapeutic applications, infection control, and water purification, today reported that is has entered into a development agreement with STERIS Corporation.

24 Mar 2010

China Sky One Medical prepares for commercial launch 13 new SFDA approved products

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced the pending commercial launch of 13 new SFDA approved products over the next few quarters.

22 Mar 2010

A.P. Pharma's NDA for APF530 in prevention of CINV: FDA issues Complete Response Letter

A.P. Pharma, Inc., a specialty pharmaceutical company, today announced that it received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for APF530 in the prevention of both acute and delayed onset chemotherapy-induced nausea and vomiting.

19 Mar 2010

TSO3 reports net loss of $9.2M for fiscal 2009

TSO3 Inc. an innovator in sterilization technology for medical devices in healthcare settings using ozone, posted sales totalling $1.3 million for the fiscal year ended December 31, 2009, compared to $2.2 million one year earlier. During the year, the Company sold five of its first generation STERIZONE(R) sterilizers and accessories, whereas it sold 13 in the preceding fiscal year.

17 Mar 2010

TSO3's STERIZONE Sterilization System exhibited under 3M brand at AORN Annual Congress

TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings using ozone, announced today that its new generation STERIZONE(R) Sterilization System, is being exhibited in the 3M(TM)booth under the 3M(TM) brand Optreoz(TM)125-Z Sterilizer at the Association of Perioperative Registered Nurses 57th Annual Congress held from March 13 to 18 in Denver, Colorado.

17 Mar 2010

MDS reports revenues of $46M for first-quarter fiscal 2010

MDS Inc., a leading provider of products and services to the global health science markets, today reported financial results and filed its unaudited interim consolidated financial statements and related Management Discussion & Analysis for the three months ended January 31, 2010. In order to simplify our disclosures, we have discontinued the use of non-GAAP measures such as adjusted EBITDA.

16 Mar 2010

NIH panel recommends delivery options for women: VBAC or cesarean

An independent panel convened this week by the National Institutes of Health confronted a troubling fact that pregnant women currently have limited access to clinicians and facilities able and willing to offer a trial of labor after previous cesarean delivery because of so-called VBAC bans.

11 Mar 2010

RTI Biologics launches BTB Select and BioCAP Select implants for use in sports medicine surgeries at AAOS 2010

RTI Biologics Inc., the Florida-based processor of orthopedic, dental, surgical specialties and other biologic implants, is launching two new biologic implants for use in sports medicine surgeries at the American Academy of Orthopaedic Surgeons annual meeting in New Orleans this week.

11 Mar 2010

MDS ends strategic repositioning with divestiture of MDS Pharma Services Early Stage business

MDS Inc., a leading provider of products and services to the global health sciences markets, today announced that it has completed the divestiture of its MDS Pharma Services Early Stage business.

9 Mar 2010

TSO3 new generation sterilizers allowed CE Mark labeling

TSO3 Inc., an innovator in sterilization technology for medical devices in healthcare settings using ozone, today announced that documentation supplied to the European Notified Body conforms to the new Medical Device Directive for Class IIb medical devices; an enhanced European standard to be enforced starting April 2010. This notification allows the Company to label its new generation sterilizers with the CE Mark, which is a requirement to place products in the European Union; the second largest sterilization market after the United States.

5 Mar 2010

Recycling medical equipment saves money and reduces waste

Wider adoption of the practice of recycling medical equipment — including laparoscopic ports and durable cutting tools typically tossed out after a single use — could save hospitals hundreds of millions of dollars annually and curb trash at medical centers, the second-largest waste producers in the United States after the food industry.

25 Feb 2010

Synovis Life Technologies reports net revenue of $15.2M for first-quarter fiscal 2010

Synovis Life Technologies, Inc., today reported financial results for the first fiscal quarter ended Jan. 31, 2010.

24 Feb 2010

TSO3 files final short form prospectus with respect to 10M common share public offering

TSO3 Inc. is pleased to announce that it has filed a final short form prospectus with the securities regulatory authorities in all provinces of Canada with respect to a previously announced public offering of 10,000,000 common shares for gross proceeds to the Company of C$16 million. The prospectus also qualifies for the distribution of 150,000 Common shares sold by Simon Robitaille, one of the Company's founders and Chief Scientific Officer, for gross proceeds of $240,000.